Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.80 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.80 |
| ▸ | TNF | P01375 | 3/20 | 0.80 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 6/20 | 0.74 |
| ▸ | NPC1 | O15118 | 6/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.71 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | MITF | O75030 | 1/20 | 0.71 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918590 | 0.86 | MEN1 (0.79) | MEN1KMT2ANOD1TNFGRIN2C | |
| SCHEMBL3916274 | 0.86 | KMT2A (0.97) | MEN1KMT2ANOD1TNFGRIN2C | |
| SCHEMBL7894757 | 0.85 | GRIN2C (1.00) | MEN1KMT2ANOD1TNFGRIN2C | |
| SCHEMBL919352 | 0.85 | MEN1 (1.00) | MEN1KMT2ANOD1TNFGRIN2C | |
| SCHEMBL23413350 | 0.84 | GLO1 (1.00) | MEN1KMT2ANOD1TNFGRIN2C | |
| SCHEMBL7903456 | 0.84 | MAPT (0.79) | ALDH1A1MAPTHPGDTDP1KDM4E | |
| SCHEMBL21247366 | 0.83 | RAB9A (1.00) | MEN1KMT2ANOD1TNFGRIN2C | |
| SCHEMBL7902040 | 0.83 | GRIN2C (0.78) | MEN1KMT2ANOD1TNFGRIN2C | |
| SCHEMBL7894754 | 0.83 | MEN1 (1.00) | MEN1KMT2ANOD1TNFGRIN2C | |
| SCHEMBL25198836 | 0.80 | MEN1 (0.74) | MEN1KMT2ANOD1TNFGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-26 | — | — | US | disclosed |
| US-10273214-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | EMORY UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | TRAYNELIS STEPHEN F (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | TRAYNELIS STEPHEN F (US) | 2014-09-18 | — | — | US | disclosed |
| US-8822462-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | EMORY UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822462-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | EMORY UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010088414-A2 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | EMORY UNIVERSITY (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273214-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | GRIN1, GRIN2A, GRIN2B | MEN1 4250/4885KMT2A 2345/4885NOD1 890/4885 |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | GRIN1, GRIN2A, GRIN2B | MEN1 4250/4885KMT2A 2345/4885NOD1 890/4885 |
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | MEN1 3538/4885KMT2A 3454/4885NOD1 410/4885 |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | GRIN1, GRIN2A, GRIN2B | MEN1 4250/4885KMT2A 2345/4885NOD1 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.